Cellipont and Secretome link to manufacture cGMP cellular therapy
In October 2023, it signed an agreement with Diakonos Oncology to develop a cell therapy, DOC1021, to treat glioblastoma ...
GlobalData on MSN22h
Interim data success for Salubris Biotherapeutics’ heart failure candidate
The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.
Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome ...
PipelineReview.com7h
Salubris Biotherapeutics Announces Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure
GAITHERSBURG, MD, USA I2, 2025 I Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today ...
Knowridge5h
Common blood pressure drug may cause a “stiff heart”
However, the benefits of beta-blockers in “stiff heart” heart failure are less clear. This condition, also known as heart ...